

Diabetes & Obesity

RESEARCH REVIEW™

Making Education Easy

Issue 141 – 2021

In this issue:

- Online weight management integrated with population health management
- All-cause mortality after bariatric surgery
- Weight loss from time-restricted eating
- DKA admissions at Middlemore
- NZ ethnic inequities in diabetes screening during pregnancy
- Auckland primary-care nurses improve foot management for diabetics
- Dietary fat type and mortality
- RYGB for obese type 1 diabetics
- Hybrid closed-loop system in type 1 diabetes
- Hypoglycaemia unawareness not eliminated by CGM
- DECLARE-TIMI 58 outcomes according to baseline glucose-lowering treatment
- CV events and hospitalisations with empagliflozin in EMPA-REG OUTCOME

Abbreviations used in this issue

BMI = body mass index
CGM = continuous glucose monitoring
CV = cardiovascular
DKA = diabetic ketoacidosis
GLP = glucagon-like peptide
HbA_{1c} = glycosylated haemoglobin
HR = hazard ratio
MI = myocardial infarction
MUFA/PUFA = mono-/polyunsaturated fatty acid
RYGB = Roux-en-Y gastric bypass
SGLT = sodium glucose cotransporter



Welcome to issue 141 of Diabetes and Obesity Research Review, our first issue for 2021.

We begin with a cluster randomised trial showing that an online weight loss programme integrated with population health management slightly but significantly improved weight loss over usual care in patients with type 2 diabetes. Two papers from the N Z Med J highlight ethnic inequities in NZ: one reports that Māori and Pasifika people and those of lower socioeconomic status were over-represented in admissions for DKA at Middlemore Hospital, while the other found that adherence to screening guidelines for diabetes in pregnancy was worse for Māori than non-Māori. On a more positive note, another paper from the N Z Med J reports that primary-care nurses in Auckland have increased the number of foot examinations and the provision of recommended foot-care education over the last decade. The issue concludes with a secondary analysis of the EMPA-REG OUTCOME trial of empagliflozin versus placebo in participants with type 2 diabetes and atherosclerotic CV disease, showing a reduced burden of CV complications and all-cause hospital admissions.

We hope you enjoy the papers selected for this issue, and we look forward to your comments and feedback.

Best regards,

Professor Jeremy Krebs

jeremykrebs@researchreview.co.nz

Effect of an online weight management program integrated with population health management on weight change

Authors: Baer HJ et al.

Summary: Overweight/obese (BMI 27–<40 kg/m²) primary-care patients aged 20–70 years with type 2 diabetes or hypertension were randomised by cluster to an online programme with (n=298) or without (n=216) additional support from nonclinical staff to monitor progress, or to usual care (n=326) in this trial. The respective mean weight changes at 12 months in the usual care, online programme only and online programme plus support arms were –1.2, –1.9 and –3.1kg, with statistically significant differences between the online programme plus support and usual care groups (p<0.001) and between the online programme plus support and online program only groups (p=0.01); the mean weight changes for the respective study arms at 18 months were –1.9, –1.1 and –2.8kg.

Comment: We all know that achieving sustained and meaningful weight loss for people with obesity is very hard. There are so many barriers to the success of weight management programmes. One such barrier is time and access to individual or group sessions with health professionals. This makes online services theoretically attractive, but few studies have shown efficacy of online programmes. This study compared an online programme enhanced by additional contact with an online programme alone or just simple education. Not surprisingly, the combined package resulted in greater weight loss – albeit very modest. To make this useful in clinical practice, the cost of the intervention has to be low, and that is primarily determined by staff costs. An economic analysis would help determine the utility of this approach in NZ.

Reference: JAMA 2020;324:1737–46

[Abstract](#)

Independent commentary by Professor Jeremy Krebs MBChB, FRACP, MD

Professor Krebs is an Endocrinologist with a particular interest in obesity and diabetes. He is a Professor with the University of Otago, and former Director of the Clinical Research Diploma at Victoria University – which he established. As well as clinical and teaching activities, Professor Krebs maintains active research interests in the area of obesity and diabetes, with a particular focus on the association between obesity and type 2 diabetes, both from an aetiology and management perspective, with a focus on nutritional aspects, bariatric surgery and diabetes service delivery. **FOR FULL BIO [CLICK HERE](#).**






Jardiance®
(empagliflozin)

FULLY FUNDED
with Special Authority criteria*
February 1st, 2021

NEW. For your patients with type 2 diabetes[†]

THE POWER TO ACCOMPLISH MORE
Above and beyond glycaemic control^{†,2}

Association between bariatric surgery and all-cause mortality

Authors: Doumouras AG et al.

Summary: The relationship between bariatric surgery and all-cause mortality was explored in Canadian population-based cohorts of 13,679 patients who had undergone bariatric surgery and 13,679 matched nonsurgical patients, followed for a median of 4.9 years. Compared with the nonsurgical group, the surgical group had a lower overall mortality rate (1.4% vs. 2.5%; adjusted HR 0.68 [95% CI 0.57, 0.81]), including for patients aged ≥ 55 years (0.53 [0.41, 0.69]), who had an absolute risk reduction of 3.3%; surgery was also associated with lower risks of CV-related mortality (0.53 [0.34, 0.84]) and cancer-related mortality (0.54 [0.36, 0.80]). The relative effects were similar between sexes, but men had a stronger association in absolute terms.

Comment: The role of bariatric surgery in weight management and metabolic health is well established. There are numerous longitudinal cohort studies and some randomised controlled trials showing benefits for weight loss, diabetes and CV disease risk. There are fewer studies reporting on mortality. This paper adds to that literature. In a case-matched design in large numbers of people undergoing bariatric surgery (80% gastric bypass), mortality was significantly lower than for matched controls after a mean of 4.9 years. The difference between cases and controls emerged early in the postoperative period and appeared to be continuing to diverge, suggesting that with longer follow-up, the benefits may be even greater.

Reference: *Ann Intern Med* 2020;173:694–703
[Abstract](#)

New Zealand Research Review subscribers can claim CPD/CME points for time spent reading our reviews from a wide range of local medical and nursing colleges. Find out more on our [CPD page](#).

Independent Content: The selection of articles and writing of summaries and commentary in this publication is completely independent of the advertisers/sponsors and their products.

Privacy Policy: Research Review will record your email details on a secure database and will not release them to anyone without your prior approval. Research Review and you have the right to inspect, update or delete your details at any time.

Disclaimer: This publication is not intended as a replacement for regular medical education but to assist in the process. The reviews are a summarised interpretation of the published study and reflect the opinion of the writer rather than those of the research group or scientific journal. It is suggested readers review the full trial data before forming a final conclusion on its merits.

Research Review publications are intended for New Zealand health professionals.

[†]38% RRR in CV death in patients with established CV disease (CAD, PAD, MI or stroke) and T2D (HR=0.62; p<0.001).^{‡2}
^{*}JARDIANCE is a funded medicine. Restrictions apply: Pharmaceutical Schedule, Hospital Medicines List. [†]In adult patients with insufficiently controlled type 2 diabetes and CAD, PAD, or a history of MI or stroke. [‡]The absolute risk for CV death was reduced from 5.9% in patients receiving standard of care plus placebo to 3.7% in patients receiving standard of care plus JARDIANCE® (p<0.001).^{1,2}

1. JARDIANCE® Data Sheet 2019 2. Zinman B et al. *N Engl J Med*. 2015;373(22):2117-2128

JARDIANCE® empagliflozin 10mg, 25mg film coated tablets Before prescribing, please review full Data Sheet which is available on request from Boehringer Ingelheim or from <http://www.medsafe.govt.nz/profs/datasheet/dsform.asp>
INDICATION: *Glycaemic control:* Treatment of type 2 diabetes mellitus (T2DM) to improve glycaemic control in adults as: *Monotherapy* - When diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance; *Add-on combination therapy* - With other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control. *Prevention of cardiovascular (CV) death:* In patients with T2DM and established CV disease to reduce the risk of CV death. To prevent CV deaths, JARDIANCE® should be used in conjunction with other measures to reduce CV risk in line with the current standard of care. **DOSAGE AND ADMINISTRATION:** Recommended starting dose is 10mg once daily taken with or without food. Dose can be increased to 25mg once daily. No dose adjustment is necessary for patients based on age, patients with eGFR ≥ 30 mL/min/1.73m² or hepatic impairment. When JARDIANCE® is used in combination with a sulfonylurea (SU) or with insulin, a lower dose of the sulfonylurea or insulin may be considered. **CONTRAINDICATIONS:** Hypersensitivity to empagliflozin or any of the excipients; patients with CKD stage 4 or 5 (severely impaired renal function including patients receiving dialysis; eGFR < 30 mL/min/1.73m² or CrCl < 30 mL/min). **WARNINGS AND PRECAUTIONS:** Patients with type 1 diabetes; diabetic ketoacidosis; necrotising fasciitis of the perineum (Fournier's gangrene); discontinue when eGFR is below 30 mL/min/1.73m²; assess renal function before treatment and regularly thereafter; patients for whom a drop in BP could pose a risk (e.g. those with known CV disease, on anti-hypertensive therapy with a history of hypotension, or aged ≥ 75 years); urinary tract infections (UTIs); rare hereditary conditions of galactose intolerance, e.g. galactosaemia; pregnancy; lactation; children (< 18 years). **INTERACTIONS:** Diuretics; insulin and SU; interference with 1,5-anhydroglucitol assay. **ADVERSE REACTIONS:** *Very common:* hypoglycaemia (when used with combination with SU or insulin). *Common:* hypoglycaemia (combination with metformin; pioglitazone with or without metformin; metformin and linagliptin); vaginal moniliasis, vulvovaginitis, balanitis and other genital infections; UTIs (including pyelonephritis and urosepsis); pruritus; allergic skin reactions (e.g. rash, urticaria); increased urination; thirst; serum lipids increased; volume depletion (patients aged ≥ 75 years). For other adverse reactions, see full Data Sheet. **ACTIONS:** Empagliflozin is a reversible, highly potent and selective competitive inhibitor of sodium-glucose co-transporter 2 (SGLT2), which is responsible for glucose absorption in the kidney. It improves glycaemic control in patients with type 2 diabetes by reducing renal glucose reabsorption through SGLT2. Through inhibition of SGLT2, excessive glucose is excreted in urine. **PRESCRIPTION MEDICINE.** JARDIANCE® is a funded medicine - Restrictions apply: Pharmaceutical Schedule, Hospital Medicines List. BOEHRINGER INGELHEIM (N.Z.) Ltd. Level 3, 2 Osterley Way. Manukau Auckland 2104. TAPS M7142 PC-NZ-100141 BOE000370

 **Boehringer Ingelheim**
Boehringer Ingelheim (NZ) Ltd.
PO Box 76216 Manukau City,
Auckland 2241. Phone 0800 802 461


Eli Lilly and Company (NZ) Ltd.
PO Box 109197 Newmarket,
Auckland 1149. Phone 0800 500 056
NZBN 9429039560643

For more information, please go to www.medsafe.govt.nz



I have the will to train
three times a week.
But I still need help to lose
weight and keep it off.

MICHAEL, AGE: 38 BMI: 34
PATIENT PORTRAYAL

Most of your patients with
obesity have the **will**.¹
You can offer them a **way**.²



Saxenda
liraglutide (rys)

Saxenda® is a **NEW** once-daily medication that
delivers **significant and sustained weight loss**
with a well-established safety profile.²⁻⁴

Find out more on saxendacare.co.nz and consider
it for your patients with obesity today.²

At 1-year:

11.2%*

mean weight loss^{2,5}
with Saxenda® in
early responders

*65% pooled population with ≥5% weight loss
at 12 weeks on 3 mg, post-hoc analyses

Saxenda® is a prescription medicine that is unfunded - a prescription charge will apply.

SAXENDA® (liraglutide (rys) 6 mg/mL). Indication: As an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index of ≥30 kg/m² (obese) or ≥27 kg/m² to <30 kg/m² (overweight) in the presence of at least one weight related comorbidity, such as dysglycaemia (pre-diabetes and type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea. Treatment should be discontinued after 12 weeks on the 3.0 mg/day dose if a patient has not lost at least 5% of their initial body weight.

Dose/administration: Administered subcutaneously once daily at any time, independent of meals, starting dose 0.6 mg/day, increase to 3.0 mg/day in increments of 0.6 mg per week. If escalation to the next dose is not tolerated for two consecutive weeks, consider discontinuing treatment. Daily doses higher than 3.0 mg are not recommended. Must not be administered intravenously or intramuscularly. **Contraindications:** Hypersensitivity to liraglutide or any of its excipients. **Warnings/Precautions:** Not for use in patients with obesity secondary to endocrinological or eating disorders or to treatment with medicinal products that may cause weight gain; children (<18 years); with a history of pancreatitis, severe renal impairment including end-stage renal disease, hepatic impairment or insufficiency, inflammatory bowel disease or diabetic gastroparesis; ≥75 years. Must not be used as a substitute for insulin. Should not be used with insulin; in combination with other prescription, over-the-counter or complementary medicines intended for weight loss. Use with caution in patients: 65-74 years; with thyroid disease; on other drugs that increase heart rate. Advise patients of the potential risk of dehydration in relation to gastrointestinal side effects and to take precautions to avoid fluid depletion. If pancreatitis is suspected, treatment should be discontinued and appropriate management initiated. If acute pancreatitis is confirmed, Saxenda® should not be restarted. A higher rate of cholelithiasis and cholecystitis has been observed in patients treated with Saxenda® - patients should be informed of the characteristic symptoms. Cholelithiasis and cholecystitis may lead to hospitalisation and cholecystectomy. Saxenda® should be discontinued for patients who experience a sustained increase in resting heart rate. Reducing the dose of concomitantly administered insulin secretagogues to reduce the risk of hypoglycaemia should be considered. **Pregnancy Category B3.** Not for use during pregnancy or breast-feeding. **Undesirable effects:** Very Common: nausea, vomiting, diarrhoea, constipation. Common: dyspepsia, abdominal pain upper, abdominal distension, eructation, flatulence, gastroesophageal reflux disease, dry mouth, gastritis, hypoglycaemia, injection site reactions, fatigue, asthenia, dizziness, dysgeusia, cholelithiasis, insomnia, increased lipase, increased amylase. (January 2020)

References: 1. Caterson ID, et al. *Diabetes Obes Metab* 2019; 21(8): 1914-24. 2. Saxenda® Data Sheet. 3. Pi-Sunyer X, et al. *N Engl J Med* 2015; 373(1):11-22, and supplementary appendix. 4. le Roux CW, et al *Lancet* 2017; 389: 1399-409. 5. Fujioka K, et al. *Obesity (Silver Spring)* 2016; 24(11): 2278-88.



Saxenda
liraglutide (rys)

Novo Nordisk Pharmaceuticals Ltd., G.S.T. 53 960 898. PO Box 51268 Pakuranga, Auckland,
New Zealand. NovoCare® Customer Care Center (NZ) 0800 689 921
www.novonordisk.co.nz. © Registered trademark of Novo Nordisk A/S.
FD20348. ANZ205X00015. TAPS(DA) NA 11872. SAX0264. Prepared: April 2020

Effects of time-restricted eating on weight loss and other metabolic parameters in women and men with overweight and obesity

Authors: Lowe DA et al.

Summary: The 12-week TREAT trial randomised 116 participants with BMI of 27–43 kg/m² to consistent meal timing or time-restricted eating. The consistent meal timing group was instructed to eat three structured meals per day, and the time-restricted eating group to eat *ad libitum* from noon until 8:00pm and completely abstain from caloric intake from 8:00pm until noon the following day. A significant decrease in weight was seen in the time-restricted eating group (−0.94kg [p=0.01]), but there was no significant change in the consistent meal timing group (−0.68kg [p=0.07] or between groups (−0.26kg [p=0.63]). In a subgroup of 50 study participants who underwent additional in-person testing, a significant within-group decrease in bodyweight was seen for the time-restricted eating group (−1.70kg [p<0.001]) and a significant difference in appendicular lean mass index was seen between groups (−0.16 kg/m² [p=0.005]), but there was no significant change for any of the other secondary outcomes assessed within or between groups. Estimated energy intake did not differ significantly between groups.

Comment: Intermittent fasting has become a popular dietary intervention to facilitate weight loss. One popular form of intermittent fasting is the 5:2 diet, and another is time-restricted eating. This study looked at the effect of time-restricted eating on weight and metabolic outcomes after 12 weeks compared with regular mealtimes. The study design is interesting because it involved remote data collection on the majority of the participants. There was modest weight loss in both groups with no difference between them – possibly all explained simply by participating in a study focusing on diet. However, it is important to understand that neither group were actually instructed to reduce total energy intake. This may explain the degree of weight loss observed, and raises the question whether additional guidance on energy intake may have assisted and potentially resulted in more weight loss and associated improvements in metabolic parameters.

Reference: *JAMA Intern Med* 2020;180:1491–9

[Abstract](#)

Diabetic ketoacidosis admissions at Middlemore Hospital

Authors: Lee JH & Orr-Walker BJ

Summary: This was an observational study of cause and patient demographics for 57 patients with type 1 diabetes who had received a total of 69 diagnoses of DKA at Middlemore Hospital between July 1, 2015 and June 30, 2016; 35% of the patients were Pasifika, 23% were Māori and 56% were from the lowest socioeconomic status quintile. Nonadherence to insulin was the reason for DKA in 59%, while infections were associated with 16% of DKA cases and new diagnoses of type 1 diabetes were associated with 14%. Nonadherence was identified as the cause of DKA for greater proportions of Pasifika and Māori patients.

Comment: Admission to hospital with DKA is always an important event and highlights a person at risk for other adverse health outcomes associated with their diabetes. Of course, some present with new type 1 diabetes, but as this paper shows clearly, apart from that, nonadherence with insulin therapy is a more common and very important reason. Furthermore, in this NZ population, more Pacific and Māori patients and those with greater deprivation were more likely to present in this way. Although not presented here, mental health issues can also be a common underlying factor in these presentations and should be considered. These are important data, which unfortunately provide further evidence of worse health status and outcomes for Māori and Pacific compared with European New Zealanders.

Reference: *N Z Med J* 2020;133(1525):34–40

[Abstract](#)

Ethnic inequities in screening for diabetes in pregnancy in New Zealand – adherence to national guidelines

Authors: Chepulis L et al.

Summary: These NZ researchers reviewed the clinical records of 807 women without known diabetes prior to pregnancy who gave birth in hospitals or community birth centres in the Waikato region during June–August 2017. Some form of diabetes screening during pregnancy was performed for 94% of the women, with 65.3% receiving HbA_{1c} level screening at <20 weeks' gestation and 33.1% being tested for gestational diabetes mellitus at 24–28 weeks' gestation, but only around a quarter (26.4%) received all Ministry of Health guideline-recommended screening. The most common screening performed was HbA_{1c} level testing (83.9% of all pregnancies), and around three quarters of the women had undergone glucose load screening at some stage during their pregnancy. Compared with the 541 non-Māori women included in the study, a significantly lower proportion of the 263 Māori women received both HbA_{1c} level and further glucose load screening during the recommended gestational windows (17.5% vs. 31.6% [*p*<0.0005]).

Comment: These rates of screening for gestational diabetes mellitus across the board, let alone the ethnic differences, suggest some form of systemic failure. Whether this is due to a lack of education or understanding by young women who are pregnant or contemplating pregnancy, or more concerning by health professionals, needs to be explored. It is pleasing to see that testing HbA_{1c} level at least is relatively good, and critical to detect women with undiagnosed type 2 diabetes, who have the worst pregnancy outcomes. However, work is required to understand and rectify the barriers to more complete glucose-based screening in the second trimester.

Reference: *N Z Med J* 2020;133(1525):106–113

[Abstract](#)

Improved foot management of people with diabetes by primary healthcare nurses in Auckland, New Zealand

Authors: Daly B et al.

Summary: Trends between 2006–2008 and 2016 in diabetes foot examinations performed by around a quarter of all Auckland-based primary-care nurses were assessed using self-administered questionnaires and telephone interviews. Compared with the 2006–2008 period, significantly more patients consulted by practice nurses received foot examinations (58% vs. 36%) and foot-care education (66% vs. 26%) in 2016, with significantly more nurses reporting routinely examining the feet of their patients (45% vs. 31%) and providing foot-care education (28% vs. 13%); these practices were associated with nurses undertaking >5 hours of diabetes education in the prior 5 years. No foot examination was performed in 43% of patients with diabetes in 2016, and of these, 23% had no record of a prior examination.

Comment: Good foot care and education is often forgotten in the management of diabetes. Thorough examination of the feet takes time and is therefore difficult to complete within the time constraints of a standard consultation in primary care. Therefore, it has become an important aspect of good primary-care practice nursing to provide this aspect of monitoring and care for people with diabetes. This paper reviews footcare in Auckland primary care and changes over a decade between 2006 and 2016. There have been major improvements across the board, which seem to be related to education and upskilling of practice nurses. Hopefully these improvements can be sustained and even further developed with well-structured systematic care.

Reference: *N Z Med J* 2020;133(1572):39–50

[Abstract](#)



This Research Review has been endorsed by The Royal New Zealand College of General Practitioners (RNZCGP) and has been approved for up to 1 CME credit for the General Practice Educational Programme (GPEP) and Continuing Professional Development (CPD) purposes. You can record your CME credits in your [RNZCGP Dashboard](#)




Time spent reading this publication has been approved for CNE by The College of Nurses Aotearoa (NZ) for RNs and NPs. For more information on how to claim CNE hours please [CLICK HERE](#).

Stay a step ahead of Diabetic Ketoacidosis (DKA)

Early detection of blood ketones can facilitate the prevention of DKA

KetoSens test strips are for use with CareSens Dual blood glucose and ketone monitoring system. 2 packs per prescription are funded for eligible patients.

Click [here](#) to order FREE KetoSens pocket guides for your patients.



KetoSens test strips fully funded on prescription. Please refer to the Pharmaceutical Schedule for full details of the conditions application for funding.

www.PharmacoDiabetes.co.nz

Pharmaco Diabetes

Pharmaco (NZ) Ltd, Auckland.

ALWAYS READ THE LABEL AND FOLLOW THE INSTRUCTIONS.
0920CS01. TAPS DA2013IM.



Association of types of dietary fats and all-cause and cause-specific mortality

Authors: Mazidi M et al., on behalf of the International Lipid Expert Panel (ILEP) & Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group

Summary: Associations between different types of dietary fats and mortality were explored in the NHANES cohort (n=24,144) with the results added to data from 29 prospective studies for a meta-analysis (n=1,164,029). In the NHANES cohort, inverse associations were detected, comparing the highest and lowest quartiles, between total fat and PUFA consumption and all-cause mortality (respective HRs 0.90 [95% CI 0.82, 0.99] and 0.81 [0.78, 0.84]), whereas a positive association was seen for saturated fatty acid consumption (1.08 [1.04, 1.11]). In the meta-analysis, inverse associations of total fat, MUFA and PUFA consumption with all-cause mortality were seen (respective HRs 0.89 [95% CI 0.82, 0.97], 0.94 [0.89, 0.99] and 0.89 [0.84, 0.94]). There was no significant association between total fat consumption and mortality due to CV disease (HR 0.93 [95% CI 0.80, 1.08]) or coronary heart disease (1.03 [0.99, 1.09]), but a positive association was detected between saturated fatty acid intake and death due to coronary heart disease (1.10 [1.01, 1.21]). Neither MUFA nor PUFA consumption was associated with death due to CV disease or coronary heart disease, and their consumption was inversely associated with death due to stroke (respective HRs 0.80 [95% CI 0.67, 0.96] and 0.84 [0.80, 0.90]).

Comment: There are few topics that cause more debate amongst nutritionists than the role of dietary fat in weight and health. This debate results in controversial extremes in dietary advice from high-fat, low-carbohydrate diets to low-fat diets. This paper explored the associations between dietary fat intake and mortality, and importantly looked at this by type of fat and by cause of death. The findings reinforce again the differences between an increased risk of saturated fat and the protective effects of PUFAs and MUFAs. This differential effect should underpin dietary advice, rather than a focus on proportion of total dietary fat, and is consistent with dietary patterns such as the Mediterranean diet.

Reference: *Clin Nutr* 2020;39:3677–86

[Abstract](#)

RACP MyCPD Program participants can claim one credit per hour (maximum of 60 credits per year) for reading and evaluating Research Reviews.

FOR MORE INFORMATION [CLICK HERE](#)

New Zealand Society for the Study of Diabetes

2021 Annual Scientific Meeting and Annual General Meeting

14th May 2021 - 15th May 2021

Wharewaka Function Centre, Waterfront, Wellington

<https://www.nzssd.org.nz/meetings/meeting/1/index.html>

Dr Rosemary Hall - NZSSD ASM 2020 Convenor



New Zealand Society
NZSSD
for the Study of Diabetes

Potential benefits and harms of gastric bypass surgery in obese individuals with type 1 diabetes

Authors: Höskuldssdóttir G et al.

Summary: This observational registry-based cohort study compared 387 patients with type 1 diabetes and obesity who had undergone RYGB surgery with 387 matched patients who had not undergone RYGB. Compared with the nonsurgical controls, patients who had undergone RYGB had lower risks of CV disease (HR 0.43 [95% CI 0.20, 0.9]), CV-related death (0.15 [0.03, 0.68]), hospitalisation for heart failure (0.32 [0.15, 0.67]) and stroke (0.18 [0.04, 0.82]), but higher risks of serious hyperglycaemic events (1.99 [1.07, 3.72]) and substance abuse (3.71 [1.03, 3.29]).

Comment: Gastric bypass surgery is a well established treatment for obesity and also for type 2 diabetes with evidence for resolution of diabetes and improved CV outcomes. However, the role of gastric bypass as a treatment for obesity in people with type 1 diabetes is less clear. It will not resolve the diabetes and makes the management of hypoglycaemia more difficult. This is a very helpful study, albeit limited by being a retrospective case-match study rather than a prospective randomised trial. Nevertheless, it provides excellent data to show that gastric bypass confers significant benefits for people with type 1 diabetes who are obese, with reductions in risk for CV disease and death. Hypoglycaemia is of concern, but with careful individual consideration, these data do support a role for gastric bypass in this group of patients.

Reference: *Diabetes Care* 2020;43:3079–85

[Abstract](#)

Six months of hybrid closed-loop versus manual insulin delivery with fingerprick blood glucose monitoring in adults with type 1 diabetes

Authors: McAuley SA et al., for the Australian JDRF Closed-Loop Research Group

Summary: Adults using multiple daily insulin injections (51%) or insulin pumps without CGM for managing their type 1 diabetes were randomised to 26 weeks of a hybrid closed-loop system (n=61) or continuation of current therapy (n=59) in this trial. Participants assigned to the hybrid closed-loop system showed an increase from baseline in the time in range on CGM during the final 3 weeks (primary outcome) from 55% to 70% at 26 weeks, with no change seen in the control group (55% at both timepoints) and a significant between-group difference (p<0.0001). Compared with the control group, the hybrid closed-loop group also had a significantly lower median HbA_{1c} level (difference -4 mmol/mol, or -0.4% [p<0.0001]) and a better diabetes-specific positive well-being score (p<0.0048) with no deterioration in diabetes distress, perceived sleep quality or cognition. There were 19 serious adverse events in the hybrid closed-loop group, nine of which were device-related, and 13 in the control group.

Comment: Insulin pump technology continues to advance, with the evolution of better subcutaneous glucose monitoring and now better algorithms to link them into closed loops. There is great hope that such closed-loop pumps will help people with type 1 diabetes to achieve excellent glucose control and minimise hypoglycaemia, and that this will translate to better long-term outcomes and close the gap in premature mortality that stubbornly persists. This study shows some benefit in this direction, with better time in range for glucose level without increased hypoglycaemia. The benefit in HbA_{1c} level was modest and did not reduce it to a nondiabetes range. This is progress, but we are not there yet.

Reference: *Diabetes Care* 2020;43:3024–33

[Abstract](#)

[CLICK HERE](#)

to read previous issues of *Diabetes & Obesity Research Review*



Associations between the time in hypoglycemia and hypoglycemia awareness status in type 1 diabetes patients using continuous glucose monitoring systems

Authors: Lin YK et al.

Summary: Patients with type 1 diabetes who were using real-time CGM systems for $\geq 86\%$ of the time were included in this cross-sectional observational study with the aim of determining if those with impaired awareness of hypoglycaemia ($n=49$) experienced more hypoglycaemia than those with normal hypoglycaemia awareness ($n=50$). Compared with patients with normal hypoglycaemia awareness, patients with impaired awareness of hypoglycaemia were significantly more likely to have CGM values of <70 and of <54 mg/dL, levels for which Clarke scores were significantly positively correlated. Patients with impaired awareness of hypoglycaemia also had significantly more events with glucose levels <70 and <54 mg/dL at ≥ 1 timepoint or lasting ≥ 20 minutes, and they experienced significantly more daytime events with glucose levels <54 mg/dL, nocturnal events with glucose levels <70 and <54 mg/dL and longer daytime event durations with glucose levels <70 and <54 mg/dL.

Comment: Hypoglycaemia unawareness is a major risk for people with type 1 diabetes for severe hypoglycaemia and limits the achievement of good glycaemic control. One of the potential benefits of CGM is to detect hypoglycaemia early and give a person the opportunity to treat it before a severe event evolves. Preventing hypoglycaemia is an important strategy to improve hypoglycaemia awareness over time. However, this study shows that unfortunately patients with impaired awareness continue to have more hypoglycaemia than those with normal awareness, despite the use of CGM.

Reference: *Diabetes Technol Ther* 2020;22:787–93

[Abstract](#)

Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents

Authors: Cahn A et al.

Summary: Cardiac and renal outcomes in patients with type 2 diabetes treated with dapagliflozin were investigated in the placebo-controlled DECLARE-TIMI 58 trial; the impact of baseline glucose-lowering agent on the treatment effect and interactions with dapagliflozin were investigated in this *post hoc* analysis. There were 14,068 baseline metformin users, 7322 baseline sulfonylurea users, 2888 baseline dipeptidyl peptidase-4 inhibitor users, 750 baseline GLP-1 receptor agonist users and 7013 baseline insulin users. The trial's composite outcome of CV-related death and hospitalisation for heart failure was reduced with dapagliflozin versus placebo, with a greater benefit seen for baseline GLP-1 receptor agonist users (HR 0.37 [95% CI 0.18, 0.78]) versus nonusers (0.86 [0.75, 0.98]; $p=0.03$ for interaction). Baseline glucose-lowering agent had no impact on the composite outcome of CV-related death, MI or ischaemic stroke (which was not significantly different for dapagliflozin versus placebo; HR 0.93 [95% CI 0.84, 1.03]) or on the renal-specific outcome (which was significantly reduced with dapagliflozin versus placebo; 0.53 [0.43, 0.66]). All of the outcomes were similar between baseline metformin users versus nonusers.

Comment: There is now abundant evidence for the cardiac and renal benefits of the SGLT-2 inhibitors as a class of drugs. This study adds further evidence to that literature and strengthens the decision by PHARMAC to fund an agent in this class for people at risk of CV disease or diabetic nephropathy. Although exploratory, the additional information from this study is the potential that a combination of an SGLT-2 inhibitor with a GLP-1 agonist may confer even greater benefit. At this stage, PHARMAC has specifically excluded funding for the combination of these drug classes. However, if this evidence base increases, then one would hope that they might review that position.

Reference: *Diabetes Obes Metab* 2021;23:29–38

[Abstract](#)

Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease

Authors: McGuire DK et al.

Summary: This secondary analysis of the EMPA-REG OUTCOME trial assessed the impact of empagliflozin on total CV events and hospital admissions; in the EMPA-REG OUTCOME trial, 7020 patients with type 2 diabetes and atherosclerotic CV disease were randomly assigned to receive empagliflozin 10mg ($n=2345$), empagliflozin 25mg ($n=2342$) or placebo ($n=2333$). Median follow-up was 3.2 years for empagliflozin recipients (pooled) and 3.1 years for placebo recipients. Compared with placebo, empagliflozin was associated with reduced risks of all major adverse CV events (rate ratio 0.78 [95% CI 0.67, 0.91]; 12.88 events prevented per 1000 patient-years), fatal/nonfatal MI (0.79 [0.62, 0.998]; 4.97 events prevented per 1000 patient-years), fatal/nonfatal MI or coronary revascularisation (0.80 [0.67, 0.95]; 11.65 events prevented per 1000 patient-years), hospitalisation for heart failure (0.58 [0.42, 0.81]; 9.67 events prevented per 1000 patient-years) and hospitalisation for any reason (0.83 [0.76, 0.91]; 50.41 events prevented per 1000 patient-years); these risk reductions were numerically greater for total events than for first events. There was no significant difference between the empagliflozin and placebo arms for total fatal/nonfatal stroke risk (rate ratio 1.10 [95% CI 0.82, 1.49]).

Comment: This is one of the main clinical trials providing the evidence underpinning SGLT-2 inhibitors and their overwhelming benefits for people with or at risk of CV events. The evidence speaks for itself and all I can say is roll on Feb 1st when we can finally start using funded empagliflozin in NZ and see these clinical benefits for the very large number of patients who will benefit. The key thing now is to systematically roll them out and achieve the greatest coverage we can.

Reference: *Lancet Diabetes Endocrinol* 2020; 8:949–59

[Abstract](#)

Get your own copy of
DIABETES & OBESITY RESEARCH REVIEW

Become one of Research Review's 32,000 NZ members

SIMPLY CLICK

I am a Health Professional

to send us an e-mail and we'll do the rest

